Eisai (ESAIY) and Biogen (BIIB) announced that the humanized anti-soluble aggregated amyloid-beta, or Abeta, monoclonal antibody Leqembi has been launched in South Korea. Leqembi received the Ministry ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

The European Medicines Agency (EMA) has recommended market approval for Alzheimer’s antibody Leqembi (lecanemab), reversing ...

Eisai Inc. announced today that screening for Study E2086-A001-101 (Study 101) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ...

Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the drug cost regulator deemed its benefits were too small to justify the price.

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

Anavex Life Sciences (NASDAQ:AVXL) traded ~10% higher in the premarket after the company said it submitted a marketing ...

BioArctic AB's (publ) partner Eisai today announced today that Leqembi® (generic name: lecanemab) has been launched in South Korea. Leqembi received approval in South Korea in May 2024 for treatment ...

Our analysis of options history for Biogen BIIB revealed 12 unusual trades. Delving into the details, we found 25% of traders ...

(Biogen, a biotechnology company, and Eisai, a pharmaceutical company, collaborated on it.) Leqembi’s approval made headlines, and for good reason. More than 6 million Americans live with ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China, and Japan gave a green light to ...